300584.SHE Nanjing Hicin Pharmaceutical Co Ltd
- Market cap
- CNY 3.84B
- P/E
- 53.4x
- P/B
- 3.49x
- ROE
- 7.6%
- Dividend yield
- 0.51%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300584.SHE undervalued?
Graham number300584.SHE trades 187.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nanjing Hicin Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Nanjing Hicin Pharmaceutical Co Ltd yet.
Nanjing Hicin Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nanjing Hicin Pharmaceutical Co Ltd
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company's products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for injection; voglibose tablets, lansoprazole enteric-coated tablets, amlodipine be…
Full company profileNanjing Hicin Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nanjing Hicin Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 281M | 455M | 712M | 925M | 706M | 578M | 526M | 518M | 504M | 671M | 820M |
| Gross Profit | 189M | 355M | 613M | 735M | 532M | 468M | 393M | 417M | 411M | 554M | 564M |
| Operating Income | 52.1M | 77.6M | 96.5M | 114M | 62.5M | 331M | 30.1M | 39.3M | 41.8M | 89.7M | 153M |
| EBITDA | 67.0M | 91.6M | 117M | 148M | 99.9M | 375M | 84.2M | 99.6M | 103M | 118M | 128M |
| Net Income | 45.2M | 65.6M | 83.2M | 97.3M | 55.2M | 286M | 32.4M | 36.3M | 40.2M | 42.1M | 83.0M |
| EPS | 0.50 | 0.56 | 0.69 | 0.81 | 0.46 | 2.38 | 0.27 | 0.30 | 0.34 | 0.35 | 0.69 |
| Balance Sheet | |||||||||||
| Total Assets | 371M | 632M | 794M | 869M | 907M | 1.30B | 1.29B | 1.41B | 1.46B | 1.53B | 1.58B |
| Total Liabilities | 94.7M | 115M | 213M | 215M | 228M | 354M | 343M | 421M | 426M | 432M | 489M |
| Shareholders' Equity | 276M | 518M | 581M | 654M | 680M | 950M | 951M | 987M | 1.02B | 1.05B | 1.09B |
| Cash & Short-term Investments | 24.5M | 74.6M | 101M | 150M | 113M | 116M | 95.1M | 46.8M | 45.8M | 66.2M | 33.4M |
| Total Debt | 32.4M | 42.6M | 120M | 124M | 170M | 180M | 178M | 253M | 303M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 37.7M | 46.6M | 77.2M | 97.3M | 73.4M | 59.9M | -5.82M | 23.9M | 60.0M | 78.1M | - |
| Capital Expenditure | 45.6M | 66.5M | 76.7M | 43.4M | 120M | 94.4M | 219M | 197M | 77.9M | 62.6M | 31.2M |
| Free Cash Flow | -7.89M | -20.0M | 538K | 53.9M | -46.7M | -34.5M | -225M | -173M | -18.0M | 15.4M | -11.5M |
| Ratios | |||||||||||
| ROE | 16.4% | 12.7% | 14.3% | 14.9% | 8.1% | 30.1% | 3.4% | 3.7% | 3.9% | 4.0% | 7.6% |
| ROA | 12.2% | 10.4% | 10.5% | 11.2% | 6.1% | 22.0% | 2.5% | 2.6% | 2.7% | 2.7% | 5.3% |
| Net Profit Margin | 16.1% | 14.4% | 11.7% | 10.5% | 7.8% | 49.4% | 6.2% | 7.0% | 8.0% | 6.3% | 10.1% |
| Debt to Equity | 0.12x | 0.08x | 0.21x | 0.19x | 0.25x | 0.19x | 0.19x | 0.26x | 0.30x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nanjing Hicin Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.51%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 46.4%
- Ex-dividend date
- Jun 25, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 19.5M | 0.16 | 46.4% |
| 2024 | CNY 13.9M | 0.12 | 34.4% |
| 2023 | CNY 6.47M | 0.05 | 17.8% |
| 2022 | CNY 30.0M | 0.25 | 92.5% |
| 2021 | CNY 15.0M | 0.12 | 5.2% |
| 2020 | CNY 30.0M | 0.25 | 54.3% |
| 2019 | CNY 24.0M | 0.20 | 24.7% |
| 2018 | CNY 24.2M | 0.20 | 29.0% |
| 2017 | CNY 25.1M | 0.21 | 38.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Apr 20, 2018.
Who owns Nanjing Hicin Pharmaceutical Co Ltd
- Insiders 54.87%
- Institutions 1.85%
- Public & others 43.28%
- Shares outstanding 120M
- Free float 52.4M
Nanjing Hicin Pharmaceutical Co Ltd company profile
- Company name
- Nanjing Hicin Pharmaceutical Co Ltd
- Ticker
- 300584.SHE
- ISIN
- CNE100002F44
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 553
- Fiscal year end
- December
- Address
- No.1 Hengfa Road, Nanjing, China, 210046
- Phone
- 86 25 8324 1873
- Website
- hicin.cn
About Nanjing Hicin Pharmaceutical Co Ltd
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company's products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for injection; voglibose tablets, lansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets; and raw materials, intermediates, and other products. Its products are used in cardiovascular and cerebrovascular, diuretic, anti-infection, digestive system, immune regulation, hypoglycemic, orthopedics, and other treatment areas. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is headquartered in Nanjing, China.
Nanjing Hicin Pharmaceutical Co Ltd management
7- Mr. Yuping CaoGM & Chairman of the Board · born 1964
- Mr. Jian Ren ChenFinancial Director · born 1969
- Mr. Mingsheng FengDeputy GM & Director · born 1978
- Mr. Li Qun WangSecretary & Deputy GM · born 1988
- Mr. Guangyao LiuDeputy General Manager · born 1989
- Mr. Wei Biao YueDeputy General Manager · born 1970
- Xiaowei LiAccounting Supervisor